Blood Screening Market Analysis By Technology (Nucleic Acid Amplification Test, ELISA, Chemiluminescence Immunoassay And Enzyme Immunoassay, Next-Generation Sequencing, And Western Blotting) And By Product (Reagent, Instrument) And Segment Forecasts, 2013 - 2024
The global blood screening market is expected to reach a value of USD 3.9 billion by 2024, based on a new report by Grand View Research, Inc. The growth of the market is attributed to the increasing screening of donor and continuous technological advancements by the market players. Demand for blood screening tests are increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry.
Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). Result of all these assays must be negative for blood donation.
Technological developments in the market increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Further Key Findings from the Study Suggest:
Nucleic acid amplification test or nucleic acid test (NAT) is expected to be the fastest growing segment during the forecast period. It comprises transcription mediated amplification (TMA) tests and polymerase chain reaction. Increasing demand of NAT over ELISA test due to high sensitivity and specificity for viral nucleic acid is contributing to the fastest growth during the forecast period.
In 2015, reagent dominated the product segment. Introduction of new assays for the detection of various diseases is expected to enable the segment to gain the maximum share of market in the coming years. For instance, in January 2015 the FDA approved Roche’s blood screening assay COBAS TaqScreen MPX Test for the detection and identification of HCV, HIV, and HBV.
In 2015, regionally North America dominated with a revenue share of more than 40%. Government initiatives, presence of major players, and more patient affordability are the major factors that contributed toward its dominance.
In August 2016, the FDA recommended the testing of all the donated blood in the U.S. and its territories for Zika virus in order to prevent transmission of this virus through the blood supply.
Asia Pacific is expected to be the fastest growing region due to increasing investment of industry players, government initiatives, and rising awareness about transmission of diseases during its transfusion.
The Red Cross in Japan entered into a contract with Grifols for nucleic acid testing (NAT) for a blood donation camp in Japan in 2014. This agreement is anticipated to propel the NAT market during the forecast period. However, low donation as compared to requirement and high cost of kits and instruments are likely to restrain the growth in low-income countries during the forecast period.
Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). Result of all these assays must be negative for blood donation.
Technological developments in the market increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Further Key Findings from the Study Suggest:
Nucleic acid amplification test or nucleic acid test (NAT) is expected to be the fastest growing segment during the forecast period. It comprises transcription mediated amplification (TMA) tests and polymerase chain reaction. Increasing demand of NAT over ELISA test due to high sensitivity and specificity for viral nucleic acid is contributing to the fastest growth during the forecast period.
In 2015, reagent dominated the product segment. Introduction of new assays for the detection of various diseases is expected to enable the segment to gain the maximum share of market in the coming years. For instance, in January 2015 the FDA approved Roche’s blood screening assay COBAS TaqScreen MPX Test for the detection and identification of HCV, HIV, and HBV.
In 2015, regionally North America dominated with a revenue share of more than 40%. Government initiatives, presence of major players, and more patient affordability are the major factors that contributed toward its dominance.
In August 2016, the FDA recommended the testing of all the donated blood in the U.S. and its territories for Zika virus in order to prevent transmission of this virus through the blood supply.
Asia Pacific is expected to be the fastest growing region due to increasing investment of industry players, government initiatives, and rising awareness about transmission of diseases during its transfusion.
The Red Cross in Japan entered into a contract with Grifols for nucleic acid testing (NAT) for a blood donation camp in Japan in 2014. This agreement is anticipated to propel the NAT market during the forecast period. However, low donation as compared to requirement and high cost of kits and instruments are likely to restrain the growth in low-income countries during the forecast period.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Data Analysis
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing donor screening
3.1.1.2 Increasing Government Initiatives
3.1.1.3 Technological Developments
3.1.2 Market restraint analysis
3.1.2.1 High Cost
3.2 Penetration & Growth Prospects Mapping
3.3 Blood Screening Market – PESTLE Analysis
3.4 Industry Analysis – Porter’s
3.5 Blood screening competitive scenario, 2015
3.5.1 Competitive landscape: Market position analysis (based on products, regional presence and strategic initiatives)
CHAPTER 4 BLOOD SCREENING MARKET TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1 Blood Screening Market: Technology Movement Analysis
4.2 Nucleic Acid Amplification Test (NAT)
4.2.1 Nucleic Acid Amplification Test (NAT) market estimates and forecasts, 2013 - 2024 (USD Million)
4.3 ELISA
4.3.1 ELISA market estimates and forecasts, 2013 - 2024 (USD Million)
4.4 Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
4.4.1 Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) market estimates and forecasts, 2013 - 2024 (USD Million)
4.5 Next-Generation Sequencing (NGS)
4.5.1 Next-generation sequencing (NGS) market estimates and forecasts, 2013 - 2024 (USD Million)
4.6 Western Blotting
4.6.1 Western blotting market estimates and forecasts, 2013 - 2024 (USD Million)
CHAPTER 5 BLOOD SCREENING MARKET PRODUCT ESTIMATES & TREND ANALYSIS
5.1 Blood Screening Market: Product Movement Analysis
5.2 Reagent
5.2.1 Reagent market estimates and forecasts, 2013 - 2024 (USD Million)
5.3 Instrument
5.3.1 Instrument market estimates and forecasts, 2013 - 2024 (USD Million)
CHAPTER 6 BLOOD SCREENING MARKET REGIONAL ESTIMATES & TREND ANALYSIS
6.1 Regional Movement Analysis & Market Share, 2015 & 2024
6.2 North America
6.2.1 North America blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.2 North America blood screening market, by product, 2013 - 2024 (USD Million)
6.2.3 U.S.
6.2.3.1 U.S. blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.3.2 U.S. blood screening market, by product, 2013 - 2024 (USD Million)
6.2.4 Canada
6.2.4.1 Canada blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.4.2 Canada blood screening market, by product, 2013 - 2024 (USD Million)
6.3 Europe
6.3.1 Europe blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.2 Europe blood screening market, by product, 2013 - 2024 (USD Million)
6.3.3 Germany
6.3.3.1 Germany blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.3.2 Germany blood screening market, by product, 2013 - 2024 (USD Million)
6.3.4 UK
6.3.4.1 UK blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.4.2 UK blood screening market, by product, 2013 - 2024 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.2 Asia Pacific blood screening market, by product, 2013 - 2024 (USD Million)
6.4.3 Japan
6.4.3.1 Japan blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.3.2 Japan blood screening market, by product, 2013 - 2024 (USD Million)
6.4.4 China
6.4.4.1 China blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.4.2 China blood screening market, by product, 2013 - 2024 (USD Million)
6.4.5 India
6.4.5.1 China blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.5.2 China blood screening market, by product, 2013 - 2024 (USD Million)
6.5 Latin America
6.5.1 Latin America blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.2 Latin America blood screening market, by product, 2013 - 2024 (USD Million)
6.5.3 Brazil
6.5.3.1 Brazil blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.3.2 Brazil blood screening market, by product, 2013 - 2024 (USD Million)
6.5.4 Mexico
6.5.4.1 Mexico blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.4.2 Mexico blood screening market, by product, 2013 - 2024 (USD Million)
6.6 MEA
6.6.1 MEA blood screening market, by technology, 2013 - 2024 (USD Million)
6.6.2 MEA blood screening market, by product, 2013 - 2024 (USD Million)
6.6.3 South Africa
6.6.3.1 South Africa blood screening market, by technology, 2013 - 2024 (USD Million)
6.6.3.2 South Africa blood screening market, by product, 2013 - 2024 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Abbott Laboratories
7.1.1 Company overview
7.1.2 Financial performance
7.1.3 Product benchmarking
7.1.4 Strategic initiatives
7.2 Danaher Corporation (Beckman Coulter)
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Product benchmarking
7.2.4 Strategic initiatives
7.3 Becton Dickinson and Company
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 Bio-Rad Laboratories, Inc.
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Grifols
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic Initiatives
7.7 Ortho-Clinical Diagnostics, Inc.
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 SOFINA s.a (Biom?rieux)
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.9 Siemens Healthcare GmbH
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.10 Thermo Fisher Scientific, Inc
7.10.1 Company overview
7.10.2 Financial performance
7.10.3 Product benchmarking
7.10.4 Strategic initiatives
1.1 Information Procurement
1.2 Data Analysis
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing donor screening
3.1.1.2 Increasing Government Initiatives
3.1.1.3 Technological Developments
3.1.2 Market restraint analysis
3.1.2.1 High Cost
3.2 Penetration & Growth Prospects Mapping
3.3 Blood Screening Market – PESTLE Analysis
3.4 Industry Analysis – Porter’s
3.5 Blood screening competitive scenario, 2015
3.5.1 Competitive landscape: Market position analysis (based on products, regional presence and strategic initiatives)
CHAPTER 4 BLOOD SCREENING MARKET TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1 Blood Screening Market: Technology Movement Analysis
4.2 Nucleic Acid Amplification Test (NAT)
4.2.1 Nucleic Acid Amplification Test (NAT) market estimates and forecasts, 2013 - 2024 (USD Million)
4.3 ELISA
4.3.1 ELISA market estimates and forecasts, 2013 - 2024 (USD Million)
4.4 Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
4.4.1 Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) market estimates and forecasts, 2013 - 2024 (USD Million)
4.5 Next-Generation Sequencing (NGS)
4.5.1 Next-generation sequencing (NGS) market estimates and forecasts, 2013 - 2024 (USD Million)
4.6 Western Blotting
4.6.1 Western blotting market estimates and forecasts, 2013 - 2024 (USD Million)
CHAPTER 5 BLOOD SCREENING MARKET PRODUCT ESTIMATES & TREND ANALYSIS
5.1 Blood Screening Market: Product Movement Analysis
5.2 Reagent
5.2.1 Reagent market estimates and forecasts, 2013 - 2024 (USD Million)
5.3 Instrument
5.3.1 Instrument market estimates and forecasts, 2013 - 2024 (USD Million)
CHAPTER 6 BLOOD SCREENING MARKET REGIONAL ESTIMATES & TREND ANALYSIS
6.1 Regional Movement Analysis & Market Share, 2015 & 2024
6.2 North America
6.2.1 North America blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.2 North America blood screening market, by product, 2013 - 2024 (USD Million)
6.2.3 U.S.
6.2.3.1 U.S. blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.3.2 U.S. blood screening market, by product, 2013 - 2024 (USD Million)
6.2.4 Canada
6.2.4.1 Canada blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.4.2 Canada blood screening market, by product, 2013 - 2024 (USD Million)
6.3 Europe
6.3.1 Europe blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.2 Europe blood screening market, by product, 2013 - 2024 (USD Million)
6.3.3 Germany
6.3.3.1 Germany blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.3.2 Germany blood screening market, by product, 2013 - 2024 (USD Million)
6.3.4 UK
6.3.4.1 UK blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.4.2 UK blood screening market, by product, 2013 - 2024 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.2 Asia Pacific blood screening market, by product, 2013 - 2024 (USD Million)
6.4.3 Japan
6.4.3.1 Japan blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.3.2 Japan blood screening market, by product, 2013 - 2024 (USD Million)
6.4.4 China
6.4.4.1 China blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.4.2 China blood screening market, by product, 2013 - 2024 (USD Million)
6.4.5 India
6.4.5.1 China blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.5.2 China blood screening market, by product, 2013 - 2024 (USD Million)
6.5 Latin America
6.5.1 Latin America blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.2 Latin America blood screening market, by product, 2013 - 2024 (USD Million)
6.5.3 Brazil
6.5.3.1 Brazil blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.3.2 Brazil blood screening market, by product, 2013 - 2024 (USD Million)
6.5.4 Mexico
6.5.4.1 Mexico blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.4.2 Mexico blood screening market, by product, 2013 - 2024 (USD Million)
6.6 MEA
6.6.1 MEA blood screening market, by technology, 2013 - 2024 (USD Million)
6.6.2 MEA blood screening market, by product, 2013 - 2024 (USD Million)
6.6.3 South Africa
6.6.3.1 South Africa blood screening market, by technology, 2013 - 2024 (USD Million)
6.6.3.2 South Africa blood screening market, by product, 2013 - 2024 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Abbott Laboratories
7.1.1 Company overview
7.1.2 Financial performance
7.1.3 Product benchmarking
7.1.4 Strategic initiatives
7.2 Danaher Corporation (Beckman Coulter)
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Product benchmarking
7.2.4 Strategic initiatives
7.3 Becton Dickinson and Company
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 Bio-Rad Laboratories, Inc.
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Grifols
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic Initiatives
7.7 Ortho-Clinical Diagnostics, Inc.
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 SOFINA s.a (Biom?rieux)
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.9 Siemens Healthcare GmbH
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.10 Thermo Fisher Scientific, Inc
7.10.1 Company overview
7.10.2 Financial performance
7.10.3 Product benchmarking
7.10.4 Strategic initiatives
LIST OF TABLES
TABLE 1 Blood screening market - global market current and forecast by regions (2015?2024) in (USD Million)
TABLE 2 North America blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 3 North America blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 4 North America blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 5 U.S. blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 6 U.S. blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 7 Canada blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 8 Canada blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 9 Europe blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 10 Europe blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 11 Europe blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 12 UK blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 13 UK blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 14 Germany blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 15 Germany blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 16 Asia Pacific blood screening market estimates and forecasts, by region, 2013 - 2024 (USD Million)
TABLE 17 Asia Pacific blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 18 Asia Pacific blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 19 Japan blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 20 Japan blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 21 China blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 22 China blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 23 India blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 24 India blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 25 Latin America blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 26 Latin America blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 27 Latin America blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 28 Brazil blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 29 Brazil blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 30 Mexico blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 31 Mexico blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 32 MEA blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 33 MEA blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 34 MEA blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 35 South Africa blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 36 South Africa blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 1 Blood screening market - global market current and forecast by regions (2015?2024) in (USD Million)
TABLE 2 North America blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 3 North America blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 4 North America blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 5 U.S. blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 6 U.S. blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 7 Canada blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 8 Canada blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 9 Europe blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 10 Europe blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 11 Europe blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 12 UK blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 13 UK blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 14 Germany blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 15 Germany blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 16 Asia Pacific blood screening market estimates and forecasts, by region, 2013 - 2024 (USD Million)
TABLE 17 Asia Pacific blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 18 Asia Pacific blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 19 Japan blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 20 Japan blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 21 China blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 22 China blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 23 India blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 24 India blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 25 Latin America blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 26 Latin America blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 27 Latin America blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 28 Brazil blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 29 Brazil blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 30 Mexico blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 31 Mexico blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 32 MEA blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
TABLE 33 MEA blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 34 MEA blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
TABLE 35 South Africa blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
TABLE 36 South Africa blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & Forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Blood screening market – PESTLE analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Blood screening market outlook key takeaways
FIG. 16 Blood screening market: Technology movement analysis
FIG. 17 Global blood screening market, by technology 2013 - 2024 (USD Million)
FIG. 18 Global blood screening market, 2013 - 2024 (USD Million)
FIG. 19 Global Nucleic Acid Amplification Test (NAT) market, 2013 - 2024 (USD Million)
FIG. 20 Global ELISA market, 2013 - 2024 (USD Million)
FIG. 21 Global Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) market, 2013 - 2024 (USD Million)
FIG. 22 Global Next-Generation Sequencing (NGS) market, 2013 - 2024 (USD Million)
FIG. 23 Global western blotting market, 2013 - 2024 (USD Million)
FIG. 24 Blood screening market: Product movement analysis
FIG. 25 Global blood screening market, by technology 2013 - 2024 (USD Million)
FIG. 26 Global Reagent market, 2013 - 2024 (USD Million)
FIG. 27 Global Instrument market, 2013 - 2024 (USD Million)
FIG. 28 Regional market place: Key takeaways
FIG. 29 Blood screening market regional outlook, 2015 & 2024
FIG. 30 North America blood screening market, 2013 - 2024 (USD Million)
FIG. 31 U.S. blood screening market, 2013 - 2024 (USD Million)
FIG. 32 Canada blood screening market, 2013 - 2024 (USD Million)
FIG. 33 Europe blood screening market, 2013 - 2024 (USD Million)
FIG. 34 Germany blood screening market, 2013 - 2024 (USD Million)
FIG. 35 UK blood screening market, 2013 - 2024 (USD Million)
FIG. 36 Asia Pacific blood screening market, 2013 - 2024 (USD Million)
FIG. 37 Japan blood screening market, 2013 - 2024 (USD Million)
FIG. 38 China blood screening market, 2013 - 2024 (USD Million)
FIG. 39 India blood screening market, 2013 - 2024 (USD Million)
FIG. 40 Latin America blood screening market, 2013 - 2024 (USD Million)
FIG. 41 Brazil blood screening market, 2013 - 2024 (USD Million)
FIG. 42 Mexico blood screening market, 2013 - 2024 (USD Million)
FIG. 43 Middle East Africa blood screening market, 2013 - 2024 (USD Million)
FIG. 44 South Africa blood screening market, 2013 - 2024 (USD Million)
FIG. 45 Strategy frameworks
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & Forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Blood screening market – PESTLE analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Blood screening market outlook key takeaways
FIG. 16 Blood screening market: Technology movement analysis
FIG. 17 Global blood screening market, by technology 2013 - 2024 (USD Million)
FIG. 18 Global blood screening market, 2013 - 2024 (USD Million)
FIG. 19 Global Nucleic Acid Amplification Test (NAT) market, 2013 - 2024 (USD Million)
FIG. 20 Global ELISA market, 2013 - 2024 (USD Million)
FIG. 21 Global Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) market, 2013 - 2024 (USD Million)
FIG. 22 Global Next-Generation Sequencing (NGS) market, 2013 - 2024 (USD Million)
FIG. 23 Global western blotting market, 2013 - 2024 (USD Million)
FIG. 24 Blood screening market: Product movement analysis
FIG. 25 Global blood screening market, by technology 2013 - 2024 (USD Million)
FIG. 26 Global Reagent market, 2013 - 2024 (USD Million)
FIG. 27 Global Instrument market, 2013 - 2024 (USD Million)
FIG. 28 Regional market place: Key takeaways
FIG. 29 Blood screening market regional outlook, 2015 & 2024
FIG. 30 North America blood screening market, 2013 - 2024 (USD Million)
FIG. 31 U.S. blood screening market, 2013 - 2024 (USD Million)
FIG. 32 Canada blood screening market, 2013 - 2024 (USD Million)
FIG. 33 Europe blood screening market, 2013 - 2024 (USD Million)
FIG. 34 Germany blood screening market, 2013 - 2024 (USD Million)
FIG. 35 UK blood screening market, 2013 - 2024 (USD Million)
FIG. 36 Asia Pacific blood screening market, 2013 - 2024 (USD Million)
FIG. 37 Japan blood screening market, 2013 - 2024 (USD Million)
FIG. 38 China blood screening market, 2013 - 2024 (USD Million)
FIG. 39 India blood screening market, 2013 - 2024 (USD Million)
FIG. 40 Latin America blood screening market, 2013 - 2024 (USD Million)
FIG. 41 Brazil blood screening market, 2013 - 2024 (USD Million)
FIG. 42 Mexico blood screening market, 2013 - 2024 (USD Million)
FIG. 43 Middle East Africa blood screening market, 2013 - 2024 (USD Million)
FIG. 44 South Africa blood screening market, 2013 - 2024 (USD Million)
FIG. 45 Strategy frameworks
